Pharmaceuticals
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based inSouth Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, ...
2023-02-03 14:34
3421
Briggs wins "National Manufacturing Award 2022" at Make UK, UK's leading Manufacturer's Organization
HONG KONG, Feb. 2, 2023 /PRNewswire/ -- CIMC Enric Holdings Limited ("CIMC Enric")and its subsidiaries (collectively, the "Company") (Hong Kong stock code: 3899.HK) are pleased to announce that, Briggs of Burton PLC ("Briggs"), a subsidiary of CIMC Enric's liquid food business, has been awarded t...
2023-02-03 13:54
4562
Servier full year 2021/22 results confirm the transformation trajectory of the Group
* Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales * Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) * Important development...
2023-02-02 14:30
2647
SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan
TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ultrasound (HIFU)...
2023-02-02 14:00
2550
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)
SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce the appointment ofMasato Sasaki as General Manager of LabPMM GK, our reference laboratory inJapan. Mr. Sasaki brings a wealth of scientific experience with him as he served at Illumina K.K. (Japan) as a leader on their cl...
2023-02-02 05:00
3487
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...
2023-02-01 20:00
2649
Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that it is advancing the clinical development of...
2023-02-01 15:00
4943
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche L...
2023-01-31 21:50
4407
Global Times: 'So much better than we had anticipated': China's rural regions embrace Spring Festival as COVID peak ebbs away
BEIJING, Jan. 31, 2023 /PRNewswire/ -- The Spring Festival is rooted in agricultural civilization. Chinese people believe the most traditional atmosphere of Spring Festival is in rural regions. Since the prevention and control of the COVID-19 epidemic has entered a new stage, questions have been...
2023-01-31 21:41
3138
Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world's deadliest neglected diseases remained woefully inadequate and largely stagnant. Specific...
2023-01-31 21:30
2591
Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang...
2023-01-31 20:30
2711
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment inAustralia, the United States, and Italy * Presented compelling bioMUSE data at two prestigious industry conferences * Granted a 20-year patent for 100 new compounds targeting Parkinson's...
2023-01-31 20:25
5402
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed t...
2023-01-31 17:40
4603
Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic
HONG KONG, Jan. 31, 2023 /PRNewswire/ -- In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donateRMB10...
2023-01-31 16:10
4530
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region
* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a double-digit royalties on Net Sales * CS Pharmaceuticals will receive exclusive rights for development and commercialization of Bersiporocin for the treatment of IPF and other respiratory indica...
2023-01-31 14:43
6264
Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autolog...
2023-01-31 09:24
3166
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical tr...
2023-01-31 08:00
3937
Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China
BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in p...
2023-01-30 23:00
3171
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
* ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. * ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. * ORSERDU is the first endocrine innovation in more than 20 years, specif...
2023-01-30 20:39
3651
Kalbe Consumer Health Crowned Winner at the Asia Pacific Enterprise Awards 2022 Regional Edition
SINGAPORE, Jan. 27, 2023 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...
2023-01-30 11:26
3320
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
41927
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
33400
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
17085
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
16389
